Bryostatin 1
- Generic Name
- Bryostatin 1
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C47H68O17
- CAS Number
- 83314-01-6
- Unique Ingredient Identifier
- 37O2X55Y9E
- Background
Bryostatin 1 has been investigated for the treatment of HIV Infection and Alzheimer's Disease.
- Associated Conditions
- -
- Associated Therapies
- -
Bryostatin 1 in Treating Patients With Myelodysplastic Syndrome
- Conditions
- First Posted Date
- 2004-07-19
- Last Posted Date
- 2013-04-05
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Registration Number
- NCT00003171
- Locations
- ๐บ๐ธ
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Bryostatin 1 in Treating Patients With Relapsed Multiple Myeloma
- Conditions
- First Posted Date
- 2004-07-19
- Last Posted Date
- 2013-04-05
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Registration Number
- NCT00002907
- Locations
- ๐บ๐ธ
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2015-04-30
- Lead Sponsor
- National Institute on Aging (NIA)
- Target Recruit Count
- 48
- Registration Number
- NCT00087425
- Locations
- ๐บ๐ธ
NIH - Warren Grant Magnuson Clinical Center, Bethesda, Maryland, United States
Bryostatin-1 in Treating Patients With Recurrent Non-Hodgkin's Lymphoma
- First Posted Date
- 2004-06-23
- Last Posted Date
- 2013-02-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00002725
- Locations
- ๐บ๐ธ
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Bryostatin 1 Plus Paclitaxel and Cisplatin in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2004-06-16
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00003242
- Locations
- ๐บ๐ธ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
- Conditions
- First Posted Date
- 2004-06-03
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00003443
- Locations
- ๐บ๐ธ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Bryostatin 1 and High Dose Cytarabine in Treating Patients With Refractory or Relapsed Leukemia or Lymphoma
- First Posted Date
- 2004-05-27
- Last Posted Date
- 2010-02-17
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 30
- Registration Number
- NCT00003079
- Locations
- ๐บ๐ธ
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
๐บ๐ธNew York Presbyterian Hospital - Cornell Campus, New York, New York, United States
๐บ๐ธMassey Cancer Center, Richmond, Virginia, United States
Bryostatin 1 in Treating Patients With Metastatic Kidney Cancer
- First Posted Date
- 2004-05-03
- Last Posted Date
- 2013-02-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00003968
- Locations
- ๐บ๐ธ
Kimball Medical Center, Lakewood, New Jersey, United States
๐บ๐ธSouth Jersey Hospital - Millville, Millville, New Jersey, United States
๐บ๐ธRiverview Medical Center, Red Bank, New Jersey, United States
Bryostatin 1 Plus Paclitaxel in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer
- First Posted Date
- 2004-04-26
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 15
- Registration Number
- NCT00005849
- Locations
- ๐บ๐ธ
University of Chicago Cancer Research Center, Chicago, Illinois, United States
๐บ๐ธFort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States
๐บ๐ธMichiana Hematology/Oncology P.C., South Bend, Indiana, United States
Bryostatin 1 Plus Cisplatin in Treating Patients With Metastatic or Unresectable Cancer
- Conditions
- First Posted Date
- 2004-04-07
- Last Posted Date
- 2012-11-09
- Lead Sponsor
- NYU Langone Health
- Registration Number
- NCT00003132
- Locations
- ๐บ๐ธ
NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.